New for ESMO 2014: the ESMO Events App. Download yours today!
Find out why you should join, what you will gain and how to apply to become a member of ESMO
ESMO’s flagship scientific journal, Annals of Oncology, publishes editorials, reviews, original articles and letters related to oncology
OncologyPRO, our scientific information and education portal, has been given a fresh, new look...
H.Joensuu explains the molecular science behind practical benefits obtained with adjuvant imatinib in sensitive GIST and offers a detailed analysis of results of various clinical trials in this setting. He also indicates how to best select patients for this treatment option.
15 Sep 2014
Stage set to determine if tyrosine kinase inhibitors will extend the lives of patients with high-risk acute ALL
10 Sep 2014
Women who received trastuzumab as part of standard treatment show greatest benefit
09 Sep 2014
ASCO issues evidenced-based information for management of patients with HER2-negative or HER2 status unknown advanced breast cancer
08 Sep 2014
Study met primary endpoint of significant progression-free survival benefit compared with standard of care
05 Sep 2014
First PD-1 checkpoint inhibitor to receive agency approval
05 Sep 2014
Read the latest ESMO position paper published in the September issue of Annals of Oncology
26 Sep - 30 Sep 2014
13 Nov - 16 Nov 2014
21 Nov - 22 Nov 2014
12 Feb - 14 Feb 2015
06 Mar - 06 Mar 2015
13 Mar - 14 Mar 2015